ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 74,321 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $30.14, for a total value of $2,240,034.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) opened at $31.74 on Tuesday. The company has a market capitalization of $3,880.00, a P/E ratio of -12.90 and a beta of 3.79. ACADIA Pharmaceuticals Inc. has a twelve month low of $25.06 and a twelve month high of $41.20.

How to Become a New Pot Stock Millionaire

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.10. The company had revenue of $35.58 million during the quarter, compared to analyst estimates of $32.03 million. ACADIA Pharmaceuticals had a negative return on equity of 67.68% and a negative net margin of 320.71%. ACADIA Pharmaceuticals’s quarterly revenue was up 571.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.61) earnings per share. equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post -2.41 EPS for the current year.

A number of research analysts recently weighed in on ACAD shares. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 5th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $50.00 price target (up from $48.00) on shares of ACADIA Pharmaceuticals in a research note on Monday, October 2nd. JPMorgan Chase & Co. set a $50.00 price target on ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, October 5th. Piper Jaffray Companies reissued a “buy” rating and set a $61.00 price objective (up from $54.00) on shares of ACADIA Pharmaceuticals in a report on Thursday, October 5th. Finally, Jefferies Group reissued a “buy” rating and set a $47.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the company’s stock. ACADIA Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $48.86.

Several hedge funds have recently added to or reduced their stakes in ACAD. San Francisco Sentry Investment Group CA bought a new position in shares of ACADIA Pharmaceuticals in the second quarter valued at approximately $125,000. Oppenheimer Asset Management Inc. grew its holdings in shares of ACADIA Pharmaceuticals by 10.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 5,133 shares of the biopharmaceutical company’s stock valued at $143,000 after acquiring an additional 468 shares in the last quarter. Turner Investments LLC bought a new position in shares of ACADIA Pharmaceuticals in the third quarter valued at approximately $188,000. Steward Partners Investment Advisory LLC bought a new position in shares of ACADIA Pharmaceuticals in the fourth quarter valued at approximately $200,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ACADIA Pharmaceuticals by 43.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 1,710 shares in the last quarter. 94.09% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.mareainformativa.com/2018/01/30/insider-selling-acadia-pharmaceuticals-inc-acad-evp-sells-2240034-94-in-stock-updated-updated-updated.html.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.